Disease · MONDO_0006781

Helicobacter pylori infectious disease

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Helicobacter pylori infectious disease. Diseases, record MONDO_0006781. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006781

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Helicobacter pylori infectious disease; Open Targets
Open Targets ID: MONDO_0006781; Open Targets
Other names: H. pylori infection, Helicobacter Infections, Helicobacter Pylori Infection, Helicobacter pylori caused disease or disorder, Helicobacter pylori disease or disorder; Open Targets
MeSH: D016481; MeSH
Highest stage of its drugs: Approval, for 4 of its 59 drugs, from EMA Human Drugs and TTD; Open Targets

Drugs59

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
VONOPRAZAN	CHEMBL2079130	Small molecule	Approval	TTD	42	40	38	Drugs and targets
UREA C 13	CHEMBL2096648	Small molecule	Approval	EMA Human Drugs and TTD	4	0	0	Drugs and targets
POLAPREZINC	CHEMBL3184454	Small molecule	Approval	TTD	1	0	0	Drugs and targets
UREA C 14	CHEMBL2096635	Small molecule	Approval	TTD	1	0	0	Drugs and targets
AMOXICILLIN	CHEMBL1082	Small molecule	Phase 3	ClinicalTrials.gov	145	145	144	Drugs and targets
CLARITHROMYCIN	CHEMBL1741	Small molecule	Phase 3	ClinicalTrials.gov	83	83	83	Drugs and targets
METRONIDAZOLE	CHEMBL137	Small molecule	Phase 3	ClinicalTrials.gov	58	58	55	Drugs and targets
ESOMEPRAZOLE	CHEMBL1201320	Small molecule	Phase 3	ClinicalTrials.gov	36	36	36	Drugs and targets
TETRACYCLINE	CHEMBL1440	Small molecule	Phase 3	ClinicalTrials.gov	35	35	32	Drugs and targets
LEVOFLOXACIN	CHEMBL5315124	Small molecule	Phase 3	ClinicalTrials.gov	31	31	30	Drugs and targets

1 to 10 of 59

See all 59 drugs

Targets16

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ATP4A	Potassium-transporting ATPase	13	Potassium-transporting ATPase blocker; Potassium-transporting ATPase inhibitor	Approval	https://conductscience.org/library/genes/495	Drugs and targets
ATP4B	Potassium-transporting ATPase	13	Potassium-transporting ATPase blocker; Potassium-transporting ATPase inhibitor	Approval	https://conductscience.org/library/genes/496	Drugs and targets
HRH2	Histamine H2 receptor	2	Histamine H2 receptor antagonist	Phase 2/3	https://conductscience.org/library/genes/3274	Drugs and targets
VDR	Vitamin D3 receptor	2	Vitamin D receptor agonist	Phase 3	https://conductscience.org/library/genes/7421	Drugs and targets
CA1	Carbonic anhydrase 1	1	Carbonic anhydrase I inhibitor	Phase 2	https://conductscience.org/library/genes/759	Drugs and targets
CA12	Carbonic anhydrase 12	1	Carbonic anhydrase XII inhibitor	Phase 2	https://conductscience.org/library/genes/771	Drugs and targets
CA2	Carbonic anhydrase 2	1	Carbonic anhydrase II inhibitor	Phase 2	https://conductscience.org/library/genes/760	Drugs and targets
CA4	Carbonic anhydrase 4	1	Carbonic anhydrase IV inhibitor	Phase 2	https://conductscience.org/library/genes/762	Drugs and targets
MMP1	Interstitial collagenase	1	Matrix metalloproteinase-1 inhibitor	Phase 3	https://conductscience.org/library/genes/4312	Drugs and targets
MMP13	Collagenase 3	1	Matrix metalloproteinase 13 inhibitor	Phase 3	https://conductscience.org/library/genes/4322	Drugs and targets

1 to 10 of 16

See all 16 targets

Trials190

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 5 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT04167670	Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori Infection	Phase 3	1,046	2022-04-05	Helicobacter Pylori Infection	AMOXICILLIN, CLARITHROMYCIN, VONOPRAZAN	Its record names the disease	ClinicalTrials.gov
NCT05857163	Efficacy and Safety of Rifasutenizol (TNP 2198), Rabeprazole and Amoxicillin in Participants With H. Pylori Infection	Phase 3	700	2025-08-17	H.Pylori Infection	AMOXICILLIN, RABEPRAZOLE, RIFASUTENIZOL	Its record names the disease	ClinicalTrials.gov
NCT03050359	Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Duodenal Ulcer Participants With or Without Helicobacter Pylori Infection	Phase 3	533	2020-06-12	Duodenal Ulcer	LANSOPRAZOLE, VONOPRAZAN FUMARATE	Its record names the disease	ClinicalTrials.gov
NCT04198363	A Study to Evaluate the Efficacy and Safety of Bismuth-Containing Quadruple Therapy With Oral Vonoprazan (TAK-438) 20 mg Compared to Esomeprazole 20 mg Twice Daily in Paticipants With Helicobacter Pylori Infection	Phase 3	510	2023-09-07	Helicobacter Pylori	AMOXICILLIN, CLARITHROMYCIN, VONOPRAZAN	Its record names the disease	ClinicalTrials.gov
NCT03198507	ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator	Phase 3	455	2020-03-16	Helicobacter Pylori Infection, Dyspepsia	AMOXICILLIN, OMEPRAZOLE	Its record names the disease	ClinicalTrials.gov
NCT00669955	Efficacy and Safety of Quadruple Therapy in Eradication of H. Pylori: A Comparison to Triple Therapy	Phase 3	440	2010-08-05	Helicobacter Infections	BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, OMEPRAZOLE, TETRACYCLINE	Its record names the disease	ClinicalTrials.gov
NCT02359435	Comparison of 12-day Reverse Hybrid Therapy and 12-day Standard Triple Therapy for Helicobacter Pylori Infection	Not applicable	440	2016-02-10	Helicobacter Pylori Infection	AMOXICILLIN, CLARITHROMYCIN, METRONIDAZOLE, PANTOPRAZOLE	Its record names the disease	ClinicalTrials.gov
NCT02159976	Compare Sequential and Quadruple Therapy for the Eradication of Helicobacter Pylori in Korea	Not applicable	390	2019-05-13	Helicobacter Pylori Infection	AMOXICILLIN, CLARITHROMYCIN, METRONIDAZOLE, PANTOPRAZOLE, TETRACYCLINE	Its record names the disease	ClinicalTrials.gov
NCT02547038	Comparing the Efficacy of Reverse Hybrid Therapy and Bismuth Quadruple Therapy	Not applicable	352	2019-06-10	Helicobacter Pylori Infection	AMOXICILLIN, CLARITHROMYCIN, METRONIDAZOLE, PANTOPRAZOLE, TETRACYCLINE	Its record names the disease	ClinicalTrials.gov
NCT02541864	Comparison of Hybrid and Bismuth Quadruple Therapies for Helicobacter Pylori Eradication	Not applicable	330	2017-08-10	Helicobacter Pylori Infection	AMOXICILLIN, BISMUTH SUBCITRATE, CLARITHROMYCIN, METRONIDAZOLE, PANTOPRAZOLE, TETRACYCLINE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 190

See all 190 trials

Comparisons in its trials50

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Test Group vs Control Group: Safety by Assessment of the Number of Participants With Adverse Events (AEs)	131 of 351	184 of 346	697	NCT05857163	Trial comparisons
Test Group vs Control Group: Eradication Rate of H.Pylori Infection	323 of 351	304 of 346	697	NCT05857163	Trial comparisons
Test Group vs Control Group: deaths from any cause	0 of 351	0 of 346	697	NCT05857163	Trial comparisons
Test Group vs Control Group: serious adverse events	2 of 351	2 of 346	697	NCT05857163	Trial comparisons
TAK-438 20 mg vs Lansoprazole 30 mg: deaths from any cause	0 of 263	0 of 268	531	NCT03050359	Trial comparisons
TAK-438 20 mg vs Lansoprazole 30 mg: serious adverse events	1 of 263	3 of 268	531	NCT03050359	Trial comparisons
Vonoprazan 20 mg vs Esomeprazole 20 mg: deaths from any cause	0 of 256	0 of 254	510	NCT04198363	Trial comparisons
Vonoprazan 20 mg vs Esomeprazole 20 mg: serious adverse events	3 of 256	5 of 254	510	NCT04198363	Trial comparisons
RHB-105 vs Active Comparator: Number of Participants With Eradication of H. Pylori	191 of 228	131 of 227	455	NCT03198507	Trial comparisons
RHB-105 vs Active Comparator: deaths from any cause	0 of 228	0 of 227	455	NCT03198507	Trial comparisons

1 to 10 of 50

See all 50 comparisons in its trials

Papers from its trials118

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40341536	RESULT	1	PubMed
36235778	RESULT	1	PubMed
35929980	RESULT	1	PubMed
35884067	RESULT	1	PubMed
35719338	RESULT	1	PubMed
35660509	RESULT	1	PubMed
34997989	RESULT	1	PubMed
34942310	RESULT	1	PubMed
34247436	RESULT	1	PubMed
33839101	RESULT	1	PubMed

1 to 10 of 118

See all 118 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006781

GET https://conductscience.org/api/diseases/v1/MONDO_0006781/drugs?page=2

API reference For AI assistants